Revisiting the Design of Phase III Clinical Trials of Antimalarial Drugs for Uncomplicated Plasmodium falciparum Malaria
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
The Policy Forum allows health policy makers around the world to discuss challenges
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“For example, inequalities in premature mortality and infant mortality by income and ethnicity in the USA decreased during the period of welfare expansion in the USA ('war on poverty' era 1966 to 1980), but they increased again during the Reagan-Bush period (1980-2002) when welfare services and healthcare coverage were cut.46”
From The COVID-19 pandemic and health inequalities (2020) · cites this paper as [46]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global distribution of clinical episodes of Plasmodium falciparum malaria
Snow, R. W., Guerra, C. A., Noor, A. M., Myint, H. Y., & Hay, S. I. (2005) · Nature · doi:10.1038/nature03342 · Cited by 2,741 · cited 3×
“In 2002, Plasmodium falciparum caused at least 0.5 billion uncomplicated clinical attacks of malaria worldwide, particularly in nonimmune young children living in Africa [1].”
BackgroundInfluentialSelf-citationPiaggio, G., Elbourne, D. R., Pocock, S. J., Evans, S. J. W., Altman, D. G., & CONSORT Group, F. T. (2012) · JAMA · doi:10.1001/jama.2012.87802 · Cited by 2,428
Reporting of Noninferiority and Equivalence Randomized Trials: An Extension of the CONSORT Statement
Piaggio, G., Elbourne, D. R., Altman, D. G., Pocock, S. J., Evans, S. J. W., & CONSORT Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.10.1152 · Cited by 1,153 · cited 2×
“can blur true differences in treatment effects and thus lead to inadvertent conclusion of non-inferiority when in fact the new drug is inferior (type I error) [46,49].”
BackgroundMethodIndicators of Life-Threatening Malaria in African Children
Marsh, K., Forster, D., Waruiru, C., Mwangi, I., Winstanley, M., Marsh, V., Newton, C., Winstanley, P., Warn, P., Peshu, N., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322102 · Cited by 1,097 · cited 1×
“malaria can progress rapidly to life-threatening severe malaria [”
BackgroundSelf-citationTrials to assess equivalence: the importance of rigorous methods: Fig 1
Jones, B., Jarvis, P., Lewis, J. A., & Ebbutt, A. F. (1996) · BMJ · doi:10.1136/bmj.313.7048.36 · Cited by 1,032
Generation of allocation sequences in randomised trials: chance, not choice
Schulz, K. F., & Grimes, D. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07683-3 · Cited by 774
Bhattarai, A., Ali, A. S., Kachur, S. P., Mårtensson, A., Abbas, A. K., Khatib, R., Al-mafazy, A.-W., Ramsan, M., Rotllant, G., Gerstenmaier, J. F., et al. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040309 · Cited by 647 · cited 1×
“], and are thus particularly valuable in situations of low or decreasing transmission rates [”
BackgroundBloland, P. B., Ringwald, P., & Snow, R. W. (2003) · Cited by 630
Self-citationAssessment of the pharmacodynamic properties of antimalarial drugs in vivo
White, N. J. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1413 · Cited by 575 · cited 3×
“be estimated by the established “in vivo test” methodology [20].”
BackgroundMethodSelf-citationInnovative lead discovery strategies for tropical diseases
Nwaka, S., & Hudson, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2144 · Cited by 521 · cited 1×
“antimalarial drugs have been described elsewhere and used as guiding principles from early discovery through clinical development [39,40].”
Research works printed but not linked: 46
- Snow, 2005, Nature, 434, 214
- Marsh, 1995, N Engl J Med, 332, 1399
- Snow, 2002, Adv Parasitol, 52, 235
- Snow, 2001, Trends Parasitol, 17, 593
- Snow, 2003, Trends Parasitol, 19, 363
- Mutabingwa, 2005, Acta Trop, 95, 305
- Bathurst, 2006, Trends Parasitol, 22, 301
- Amin, 2007, Malar J, 6, 72
- Stepniewska, 2006, Malar J, 5, 127
- Kamya, 2007, PLoS Clin Trials, 2, e20
- Staedke, 2004, Lancet, 364, 1950
- Uhlemann, 2007, J Infect Dis, 195, 134
- Bhattarai, 2007, PLoS Med, 4, e309
- Laufer, 2007, Am J Trop Med Hyg, 77, 160
- Borrmann, 2008, Antimicrob Agents Chemother, 52, 1799
- Piola, 2005, Lancet, 365, 1467
- Price, 2007, Malar J, 6, 119
- Barnes, 2008, Trends Parasitol, 24, 127
- White, 1997, Antimicrob Agents Chemother, 41, 1413
- Djimde, 2003, Am J Trop Med Hyg, 69, 558
- Stepniewska, 2004, Antimicrob Agents Chemother, 48, 4271
- Price, 2006, Clin Infect Dis, 42, 1570
- Epstein, 2007, J Infect Dis, 196, 145
- Guthmann, 2006, Antimicrob Agents Chemother, 50, 3734
- Lee, 2006, J Infect Dis, 193, 1160
- Slater, 2005, Am J Trop Med Hyg, 73, 256
- Gatton, 2008, Trends Parasitol, 24, 68
- Collins, 2006, Malar J, 5, 122
- Farnert, 2001, Trans R Soc Trop Med Hyg, 95, 225
- Imwong, 2007, J Infect Dis, 195, 927
- White, 2008, Malar J, 7, 9
- Olliaro, 2008, Trop Med Int Health, 13, 83
- Smith, 1994, Stat Med, 13, 2345
- Staedke, 2001, Lancet, 358, 368
- Zongo, 2007, Lancet, 369, 491
- Greenhouse, 2007, Antimicrob Agents Chemother, 51, 3096
- Nwaka, 2006, Nat Rev Drug Discov, 5, 941
- Ratcliff, 2007, Lancet, 369, 757
- Tarning, 2005, Antimicrob Agents Chemother, 49, 5127
- Schulz, 2002, Lancet, 359, 515
- Myint, 2004, Trans R Soc Trop Med Hyg, 98, 73
- Jones, 1996, BMJ, 313, 36
- Piaggio, 2006, JAMA, 295, 1152
- Machekano, 2008, Stat Methods Med Res, 17, 191
- Rothmann, 2003, Stat Med, 22, 239
- Price, 2007, Antimicrob Agents Chemother, 51, 4090
Cited by
The COVID-19 pandemic and health inequalities
Bambra, C., Riordan, R., Ford, J., & Matthews, F. (2020) · Journal of Epidemiology and Community Health · doi:10.1136/jech-2020-214401 · Cited by 2,118
Beckfield, J., & Krieger, N. (2009) · Epidemiologic Reviews · doi:10.1093/epirev/mxp002 · Cited by 384
Bambra, C. (2011) · Journal of Epidemiology and Community Health · doi:10.1136/jech.2011.136333 · Cited by 284
Borrmann, S., Sasi, P. G., Mwai, L., Bashraheil, M. M., Abdallah, A. M., Muriithi, S., Frühauf, H., Schaub, B., Pfeil, J., Peshu, J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026005 · Cited by 134
“Reinfection rates by day 84, which could have confounded PCRbased classification of recrudescent primary infections [22], were high but did not change over time (P.”
BackgroundSelf-citationThe perils of PCR: can we accurately ‘correct’ antimalarial trials?
Juliano, J. J., Gadalla, N. B., Sutherland, C. J., & Meshnick, S. R. (2010) · Trends in Parasitology · doi:10.1016/j.pt.2009.12.007 · Cited by 52
“For antimalarial trials, these could include [3]:”
Background
Metadata
- Authors
- Borrmann, S., Peto, T., Snow, R. W., Gutteridge, W., & White, N. J.
- Affiliations
- Kenya Medical Research Institute (KE)
- Heidelberg University (DE)
- Corresponding author
- Borrmann, Steffen
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-11-18
- Volume
- 5
- Issue
- 11
- Pages
- e227
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC2586344
- OpenAlex
- W2026681785
- Cited by
- 15
- References
- 49
- Citations by year
- 2022: 2 · 2021: 1 · 2020: 1 · 2019: 1 · 2017: 1 · 2014: 1 · 2012: 1
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Greater South Information System
- Funders
- Wellcome Trust (079080)
- Deutsche Forschungsgemeinschaft (SFB 544, A7, SFB544)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Phytochemical compounds biological activities
- Keywords
- antimalarial drugs, trial design, uncomplicated malaria, Plasmodium falciparum, malaria treatment efficacy, health policy
- MeSH terms
- Animals, Antimalarials, Drug Therapy, Combination, Humans, Plasmodium falciparum, Survival Analysis, Malaria, Falciparum, Treatment Outcome, Clinical Trials, Phase III as Topic, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Revisiting the Design of Phase III Clinical Trials of Antimalarial Drugs for Uncomplicated Plasmodium falciparum Malaria. https://app.cochat.ai/papers/10.1371/journal.pmed.0050227
- The paper
- Borrmann, S., Peto, T., Snow, R. W., Gutteridge, W., & White, N. J. (2008). Revisiting the Design of Phase III Clinical Trials of Antimalarial Drugs for Uncomplicated Plasmodium falciparum Malaria. PLoS Medicine. https://doi.org/10.1371/journal.pmed.0050227
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.